GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps

PRESS RELEASE FDA Approval

02/08/2021

GSK (29 กรกฎาคม 2021)

GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This new indication for mepolizumab is for the add-on maintenance treatment of CRSwNP in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

Related News

Vericiguat approved in Japan to treat patients with chronic heart failure

Berlin, Germany, June 23, 2021 – Bayer announced today that the Ministry of Health, Labour, and Welfare (MHLW) in Japan has approved soluble guanylate...

01/07/2021

PRESS RELEASE FDA Approval


Santen Receives U.S. FDA Approval for Verkazia (Cyclosporine Ophthalmic Emulsion, 0.1%) for the Treatment of Vernal Keratoconjunctivitis in Children and Adults

June 24, 2021, Osaka, Japan– Santen Pharmaceutical Co., Ltd. (hereinafter, Santen), today announced that the U.S. Food and Drug Administration (FDA) h...

01/07/2021

PRESS RELEASE FDA Approval

New DUPIXENT® (dupilumab) data showcasing improvements across four type 2 inflammatory diseases to be presented at 2021 AAAAI annual meeting

To discover more on this topic, please tap 'Read more'.

02/02/2021

PRESS RELEASE Research Findings

ASEC Frontier (Thailand) Co., Ltd

Address : 1 Empire Tower, Unit 1509 15th floor South Sathorn road Yannawa Sathorn Bangkok, Thailand 10120

Tel : +662-118-0873

Email : info@medical-leaders-thailand.com

Website : www.asec-frontier.com

 

Contact Us